LATEST NEWS   PM Anwar, Turkmenistan President Serdar Berdimuhamedov witnessed the signing of a strategic cooperation agreement between Petronas and Turkmenistan authorities-- PMO | At 6 pm, the ringgit eased to 4.1340/1395 versus the US dollar from Thursday's close of 4.1145/1195 | The collaboration opens up space for more strategic engagements in future, including exploring the great potential of Turkmenistan's natural gas sector, which has among the world's largest gas reserves - PMO | Gabungan Kelab Media Malaysia (GKMM) state affiliates receive RM10,000, GKMM receive RM30,000 from Communications Ministry - Fahmi | The achievement comes as Malaysia and Turkmenistan mark 30 years of cooperation in the energy sector, which has been a key pillar of bilateral relations between the two countries -- PMO | 
BUSINESS • 26/05/2026 10:41 AM

AGC Biologics To Support Teikoku Seiyaku Lumbar Disc Herniation Therapy Development

KUALA LUMPUR, May 26 (Bernama) -- AGC Biologics has been selected by Teikoku Seiyaku Co Ltd to provide microbial contract development and manufacturing services for KTP-001, a recombinant human matrix metalloproteinase-7 (rhMMP-7) therapy being developed to treat lumbar disc herniation.

According to AGC Biologics in a statement, the agreement covers cell bank creation, process development and Good Manufacturing Practice (GMP) manufacturing for clinical trials.

AGC Biologics’ Heidelberg site General Manager, Dieter Kramer said the company would apply its microbial development expertise to establish a strong foundation for the therapy’s manufacturing programme.

Meanwhile, Teikoku Seiyaku Director and Executive Officer, Dr Hiroyuki Kubo said AGC Biologics was selected for its experience in microbial manufacturing and global operational footprint.

He said the collaboration would support the development of a potential new treatment option for patients with lumbar disc herniation.

Initial cell bank creation activities will be carried out at AGC Biologics’ microbial centre in Heidelberg, Germany, before the project transitions to the company’s Chiba facility in Japan for process development and GMP manufacturing.

AGC Biologics said the partnership also highlights its global microbial manufacturing network spanning facilities in Japan, the United States, Germany and Denmark, enabling supply chain flexibility and production continuity for drug developers across different regions.

AGC Biologics is a global contract development and manufacturing organisation (CDMO) providing development and manufacturing services for biopharmaceutical products, including therapeutic proteins, plasmid DNA, messenger RNA, viral vectors and genetically engineered cells.

-- BERNAMA

More News

Categories

Tags